Efficacy and safety of fruquintinib combined with serplulimab as 1 st line treatment in metastatic or unresectable non-clear cell renal cell carcinoma (nccRCC): Updated results from a single-arm, multicentre clinical trial.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jiwei Huang, Xiaoyi Hu, Hang Wang, Jianming Guo, Wei Xue
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4407700337